Skip to main
KZR
KZR logo

KZR Stock Forecast & Price Target

KZR Analyst Ratings

Based on 2 analyst ratings
Hold
Strong Buy 0%
Buy 0%
Hold 100%
Sell 0%
Strong Sell 0%

Bulls say

Kezar Life Sciences has recently made notable progress in its clinical development pipeline, particularly with the lifting of the partial clinical hold for KZR-616, which bodes well for its risk–benefit profile in autoimmune hepatitis (AIH). The potential full removal of the clinical hold in lupus nephritis (LN) represents a significant opportunity for the company, as it may lead to resumed development and subsequent pursuit of regulatory approval in this disease setting. Overall, these developments are viewed positively, as they enhance investor confidence and could expand the commercial outlook for Kezar's key assets.

Bears say

Kezar Life Sciences Inc has reported a substantial increase in operating expenses, which may strain financial resources and hinder future growth potential. Furthermore, the company's reliance on advancing its clinical pipeline, particularly its lead candidates Zetomipzomib and KZR-261, poses significant risks given the inherent uncertainties in clinical trial outcomes and regulatory approvals. Lastly, the lack of revenue generation at this stage amplifies concerns about long-term sustainability and the ability to fund ongoing development initiatives.

KZR has been analyzed by 2 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 100% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kezar Life Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kezar Life Sciences Inc (KZR) Forecast

Analysts have given KZR a Hold based on their latest research and market trends.

According to 2 analysts, KZR has a Hold consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kezar Life Sciences Inc (KZR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.